Tiziana Life Sciences Ltd (NASDAQ:TLSA - Get Free Report) was the recipient of a large drop in short interest in the month of December. As of December 15th, there was short interest totalling 170,100 shares, a drop of 18.3% from the November 30th total of 208,100 shares. Currently, 0.2% of the shares of the company are sold short. Based on an average trading volume of 306,000 shares, the days-to-cover ratio is currently 0.6 days.
Institutional Trading of Tiziana Life Sciences
An institutional investor recently raised its position in Tiziana Life Sciences stock. Zhang Financial LLC grew its holdings in Tiziana Life Sciences Ltd (NASDAQ:TLSA - Free Report) by 24.2% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 69,387 shares of the company's stock after acquiring an additional 13,500 shares during the quarter. Zhang Financial LLC owned 0.07% of Tiziana Life Sciences worth $67,000 as of its most recent filing with the Securities and Exchange Commission.
Tiziana Life Sciences Stock Down 4.2 %
TLSA stock traded down $0.03 during mid-day trading on Friday, reaching $0.67. 788,226 shares of the stock traded hands, compared to its average volume of 227,787. The business has a 50-day moving average of $0.93 and a two-hundred day moving average of $0.95. Tiziana Life Sciences has a 52 week low of $0.41 and a 52 week high of $1.74.
Tiziana Life Sciences Company Profile
(
Get Free Report)
Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases.
Further Reading
Before you consider Tiziana Life Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tiziana Life Sciences wasn't on the list.
While Tiziana Life Sciences currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
